{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T07:53:05Z","timestamp":1787730785285,"version":"build-2784847793"},"reference-count":40,"publisher":"Akademiai Kiado Zrt.","issue":"20","license":[{"start":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T00:00:00Z","timestamp":1747526400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2025,5,18]]},"abstract":"A m\u00e1jelzs\u00edrosod\u00e1s az egyik leggyakoribb id\u00fclt m\u00e1jbetegs\u00e9gg\u00e9 v\u00e1lt vil\u00e1gszerte.\n Progresszi\u00f3ja sor\u00e1n steatohepatitis, fibrosis, cirrhosis, valamint\n hepatocellularis carcinoma is kialakulhat. A metabolikus eredet\u0171 zs\u00edrm\u00e1jbetegs\u00e9g\n a feln\u0151ttek k\u00f6zel 30%-\u00e1ban fordul el\u0151, a diabetes mellitusban szenved\u0151ket\n nagyobb m\u00e9rt\u00e9kben \u00e9rinti, 2-es t\u00edpus\u00fa diabetes mellitus eset\u00e9n 70%-os, 1-es\n t\u00edpus\u00fa diabetes mellitusban 30\u201340%-os az el\u0151fordul\u00e1sa. A metabolikus eredet\u0171\n zs\u00edrm\u00e1jbetegs\u00e9g glob\u00e1lis eg\u00e9szs\u00e9g\u00fcgyi terhe nemcsak a m\u00e1jeredet\u0171 (p\u00e9ld\u00e1ul\n cirrhosis, m\u00e1jel\u00e9gtelens\u00e9g vagy hepatocellularis carcinoma), hanem az\n extrahepaticus (p\u00e9ld\u00e1ul cardiovascularis, daganatos) sz\u00f6v\u0151dm\u00e9nyek fokozott\n kock\u00e1zat\u00e1t is jelenti. Mind az 1-es, mind a 2-es t\u00edpus\u00fa, zs\u00edrm\u00e1jbetegs\u00e9ggel\n sz\u00f6v\u0151d\u00f6tt cukorbetegek hal\u00e1loz\u00e1sa nagyobb ar\u00e1ny\u00fa. Ezek a betegcsoportok fokozott\n kock\u00e1zatnak vannak kit\u00e9ve nemcsak a sz\u00edv-\u00e9r rendszeri betegs\u00e9gek, hanem a\n diabeteses retinopathia \u00e9s nephropathia kialakul\u00e1s\u00e1val szemben is, a\n zs\u00edrm\u00e1jbetegs\u00e9ggel nem t\u00e1rsult diabetesesekhez k\u00e9pest. \u00d6sszefoglal\u00f3nkban\n \u00e1ttekintj\u00fck azt, hogy az 1-es, illetve 2-es t\u00edpus\u00fa diabetes mellitus \u00e9s a\n m\u00e1jelzs\u00edrosod\u00e1s egy\u00fcttes fenn\u00e1ll\u00e1sa hogyan befoly\u00e1solja a diabeteses macro- \u00e9s\n microvascularis sz\u00f6v\u0151dm\u00e9nyek el\u0151fordul\u00e1s\u00e1nak gyakoris\u00e1g\u00e1t. Orv Hetil. 2025;\n 166(20): 759\u2013767.<\/jats:p>","DOI":"10.1556\/650.2025.33294","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T11:29:52Z","timestamp":1747654192000},"page":"759-767","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":2,"title":["A metabolikus eredet\u0171 zs\u00edrm\u00e1jbetegs\u00e9g kapcsolata a diabetes mellitus sz\u00f6v\u0151dm\u00e9nyeivel"],"prefix":"10.1556","volume":"166","author":[{"given":"Brigitta","family":"Kozma","sequence":"first","affiliation":[{"name":"R\u00e1ckeve V\u00e1ros Szakorvosi Rendel\u0151int\u00e9zet R\u00e1ckeve Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Egresi","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Seb\u00e9szeti, Transzplant\u00e1ci\u00f3s \u00e9s Gasztroenterol\u00f3giai Klinika Budapest, Szentkir\u00e1lyi u. 46., 1088 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9za","family":"Nagy","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati \u00e9s Hematol\u00f3giai Klinika Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anik\u00f3","family":"Somogyi","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati \u00e9s Hematol\u00f3giai Klinika Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Bl\u00e1zovics","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, K\u00eds\u00e9rletes Kardiol\u00f3giai \u00e9s Seb\u00e9szeti M\u0171t\u00e9ttani Tansz\u00e9k Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krisztina","family":"Hagym\u00e1si","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Seb\u00e9szeti, Transzplant\u00e1ci\u00f3s \u00e9s Gasztroenterol\u00f3giai Klinika Budapest, Szentkir\u00e1lyi u. 46., 1088 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"425","reference":[{"key":"R1","doi-asserted-by":"crossref","unstructured":"Younossi ZM, Golabi P, Paik JM, et al. The global epidemiology of\n nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis\n (NASH): a systematic review. Hepatology 2023; 77: 1335\u20131347.","DOI":"10.1097\/HEP.0000000000000004"},{"key":"R2","doi-asserted-by":"crossref","unstructured":"Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic\n dysfunction-associated fatty liver disease: an international expert consensus\n statement. J Hepatol. 2020; 73: 202\u2013209.","DOI":"10.1016\/j.jhep.2020.07.045"},{"key":"R3","doi-asserted-by":"crossref","unstructured":"Ajmera V, Kim BK, Yang K, et al. Liver stiffness on magnetic\n resonance elastography and the MEFIB index and liver-related outcomes in\n nonalcoholic fatty liver disease: a systematic review and meta-analysis of\n individual participants. Gastroenterology 2022; 163:\n 1079\u20131089.e5.","DOI":"10.1053\/j.gastro.2022.06.073"},{"key":"R4","doi-asserted-by":"crossref","unstructured":"Mantovani A, Csermely A, Petracca G, et al. Non-alcoholic fatty\n liver disease and risk of fatal and non-fatal cardiovascular events: an updated\n systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021; 6:\n 903\u2013913.","DOI":"10.1016\/S2468-1253(21)00308-3"},{"key":"R5","doi-asserted-by":"crossref","unstructured":"P\u00e1r A, P\u00e1r G. Alcoholic liver disease \u2013 2023. [Alkoholos m\u00e1jbetegs\u00e9g\n \u2013 2023.] Orv Hetil. 2023; 164: 1846\u20131864. [Hungarian]","DOI":"10.1556\/650.2023.32921"},{"key":"R6","doi-asserted-by":"crossref","unstructured":"Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;\n 62(1 Suppl): S47\u2013S64.","DOI":"10.1016\/j.jhep.2014.12.012"},{"key":"R7","doi-asserted-by":"crossref","unstructured":"Park J, Kim G, Kim H, et al. The association of hepatic steatosis\n and fibrosis with heart failure and mortality. Cardiovasc Diabetol. 2021; 20:\n 197.","DOI":"10.1186\/s12933-021-01374-8"},{"key":"R8","doi-asserted-by":"crossref","unstructured":"Park J, Kim G, Kim BS, et al. The associations of hepatic steatosis\n and fibrosis using fatty liver index and BARD score with cardiovascular outcomes\n and mortality in patients with new-onset type 2 diabetes: a nationwide cohort\n study. Cardiovasc Diabetol. 2022; 21: 53.","DOI":"10.1186\/s12933-022-01483-y"},{"key":"R9","doi-asserted-by":"crossref","unstructured":"Park J, Kim G, Kim H, et al. The associations between changes in\n hepatic steatosis and heart failure and mortality: a nationwide cohort study.\n Cardiovasc Diabetol. 2022; 21: 287.","DOI":"10.1186\/s12933-022-01725-z"},{"key":"R10","doi-asserted-by":"crossref","unstructured":"Adams LA, Harmsen S, St Sauver JL, et al. Nonalcoholic fatty liver\n disease increases risk of death among patients with diabetes: a community-based\n cohort study. Am J Gastroenterol. 2010; 105: 1567\u20131573.","DOI":"10.1038\/ajg.2010.18"},{"key":"R11","doi-asserted-by":"crossref","unstructured":"Vieira Barbosa J, Milligan S, Frick A, et al. Fibrosis-4 Index as an\n independent predictor of mortality and liver-related outcomes in NAFLD. Hepatol\n Commun. 2022; 6: 765\u2013779.","DOI":"10.1002\/hep4.1841"},{"key":"R12","doi-asserted-by":"crossref","unstructured":"Vieira Barbosa J, Milligan S, Frick A, et al. Fibrosis-4 index can\n independently predict major adverse cardiovascular events in nonalcoholic fatty\n liver disease. Am J Gastroenterol. 2022; 117: 453\u2013461.","DOI":"10.14309\/ajg.0000000000001606"},{"key":"R13","doi-asserted-by":"crossref","unstructured":"Targher G, Bertolini L, Poli F, et al. Nonalcoholic fatty liver\n disease and risk of future cardiovascular events among type 2 diabetic patients.\n Diabetes 2005; 54: 3541\u20133546.","DOI":"10.2337\/diabetes.54.12.3541"},{"key":"R14","doi-asserted-by":"crossref","unstructured":"Wild SH, Walker JJ, Morling JR, et al. Cardiovascular disease,\n cancer, and mortality among people with type 2 diabetes and alcoholic or\n nonalcoholic fatty liver disease hospital admission. Diabetes Care 2018; 41:\n 341\u2013347.","DOI":"10.2337\/dc17-1590"},{"key":"R15","doi-asserted-by":"crossref","unstructured":"Zhou YY, Zhou XD, Wu SJ, et al. Synergistic increase in\n cardiovascular risk in diabetes mellitus with nonalcoholic fatty liver disease:\n a meta-analysis. Eur J Gastroenterol Hepatol. 2018; 30:\n 631\u2013636.","DOI":"10.1097\/MEG.0000000000001075"},{"key":"R16","doi-asserted-by":"crossref","unstructured":"Trivedi HD, Tran Q, Fricker Z, et al. Type 2 diabetes complications\n are associated with liver fibrosis independent of hemoglobin A1c. Ann Hepatol.\n 2023; 28: 101087.","DOI":"10.1016\/j.aohep.2023.101087"},{"key":"R17","doi-asserted-by":"crossref","unstructured":"Mertens J, Van Gaal LF, Francque SM, et al. NAFLD in type 1\n diabetes: overrated or underappreciated? Ther Adv Endocrinol Metab. 2021; 12:\n 20420188211055557.","DOI":"10.1177\/20420188211055557"},{"key":"R18","doi-asserted-by":"crossref","unstructured":"Livingstone SJ, Levin D, Looker HC, et al. Estimated life expectancy\n in a Scottish cohort with type 1 diabetes, 2008\u20132010. JAMA 2015; 313:\n 37\u201344.","DOI":"10.1001\/jama.2014.16425"},{"key":"R19","doi-asserted-by":"crossref","unstructured":"Targher G, Bertolini L, Padovani R, et al. Prevalence of\n non-alcoholic fatty liver disease and its association with cardiovascular\n disease in patients with type 1 diabetes. J Hepatol. 2010; 53:\n 713\u2013718.","DOI":"10.1016\/j.jhep.2010.04.030"},{"key":"R20","doi-asserted-by":"crossref","unstructured":"Zhang L, Guo K, Lu J, et al. Nonalcoholic fatty liver disease is\n associated with increased carotid intima-media thickness in type 1 diabetic\n patients. Sci Rep. 2016; 6: 26805.","DOI":"10.1038\/srep26805"},{"key":"R21","doi-asserted-by":"crossref","unstructured":"Targher G, Pichiri I, Zoppini G, et al. Increased prevalence of\n cardiovascular disease in type 1 diabetic patients with non-alcoholic fatty\n liver disease. J Endocrinol Invest. 2012; 35: 535\u2013540.","DOI":"10.1111\/j.1464-5491.2011.03427.x"},{"key":"R22","doi-asserted-by":"crossref","unstructured":"Mantovani A, Mingolla L, Rigolon R, et al. Nonalcoholic fatty liver\n disease is independently associated with an increased incidence of\n cardiovascular disease in adult patients with type 1 diabetes. Int J Cardiol.\n 2016; 225: 387\u2013391.","DOI":"10.1016\/j.ijcard.2016.10.040"},{"key":"R23","doi-asserted-by":"crossref","unstructured":"Garofolo M, Lucchesi D, Giambalvo M, et al. Fatty liver index is an\n independent risk factor for all\u2011cause mortality and major cardiovascular events\n in type 1 diabetes: an 11\u2011year observational study. Cardiovasc Diabetol. 2024;\n 23: 85.","DOI":"10.1186\/s12933-024-02171-9"},{"key":"R24","doi-asserted-by":"crossref","unstructured":"Mantovani A, Morieri ML, Palmisano L, et al. Hepatic steatosis with\n significant fibrosis is associated with an increased 10-year estimated risk of\n cardiovascular disease in adults with type 1 diabetes mellitus. Cardiovasc\n Diabetol. 2023; 22: 204.","DOI":"10.1186\/s12933-023-01945-x"},{"key":"R25","doi-asserted-by":"crossref","unstructured":"Targher G, Bertolini L, Chonchol M, et al. Non-alcoholic fatty liver\n disease is independently associated with an increased prevalence of chronic\n kidney disease and retinopathy in type 1 diabetic patients. Diabetologia 2010;\n 53: 1341\u20131348.","DOI":"10.1007\/s00125-010-1720-1"},{"key":"R26","doi-asserted-by":"crossref","unstructured":"Targher G, Mantovani A, Pichiri I, et al. Non-alcoholic fatty liver\n disease is independently associated with an increased incidence of chronic\n kidney disease in patients with type 1 diabetes. Diabetes Care 2014; 37:\n 1729\u20131736.","DOI":"10.2337\/dc13-2704"},{"key":"R27","doi-asserted-by":"crossref","unstructured":"Tripolino C, Irace C, Cutruzzol\u00e0 A, et al. Hepatic steatosis index\n is associated with type 1 diabetes complications. Diabetes Metab Syndr Obes.\n 2019; 12: 2405\u20132410.","DOI":"10.2147\/DMSO.S221969"},{"key":"R28","doi-asserted-by":"crossref","unstructured":"Targher G, Pichiri I, Zoppini G, et al. Increased prevalence of\n chronic kidney disease in patients with type 1 diabetes and non-alcoholic fatty\n liver. Diabet Med. 2012; 29: 220\u2013226.","DOI":"10.1111\/j.1464-5491.2011.03427.x"},{"key":"R29","doi-asserted-by":"crossref","unstructured":"Mantovani A, Morieri ML, Aldigeri R, et al. MASLD, hepatic steatosis\n and fibrosis are associated with the prevalence of chronic kidney disease and\n retinopathy in adults with type 1 diabetes mellitus. Diabetes Metab. 2024; 50:\n 101497.","DOI":"10.1016\/j.diabet.2023.101497"},{"key":"R30","doi-asserted-by":"crossref","unstructured":"Mantovani A, Rigolon R, Mingolla L, et al. Nonalcoholic fatty liver\n disease is associated with an increased prevalence of distal symmetric\n polyneuropathy in adult patients with type 1 diabetes. J Diabetes Complications\n 2017; 31: 1021\u20131026.","DOI":"10.1016\/j.jdiacomp.2017.01.024"},{"key":"R31","doi-asserted-by":"crossref","unstructured":"Forlani G, Giorda C, Manti R, et al. The burden of NAFLD and its\n characteristics in a nationwide population with type 2 diabetes. J Diabetes Res.\n 2016; 2016: 2931985.","DOI":"10.1155\/2016\/2931985"},{"key":"R32","doi-asserted-by":"crossref","unstructured":"Mendez-Sanchez N, Cruz-Ramon VC, Ramirez-Perez OL, et al. New\n aspects of lipotoxicity in nonalcoholic steatohepatitis. Int J Mol Sci. 2018;\n 19: 2034.","DOI":"10.3390\/ijms19072034"},{"key":"R33","doi-asserted-by":"crossref","unstructured":"Akazawa Y, Nakao K. To die or not to die: death signaling in\n nonalcoholic fatty liver disease. J Gastroenterol. 2018; 53:\n 893\u2013906.","DOI":"10.1007\/s00535-018-1451-5"},{"key":"R34","doi-asserted-by":"crossref","unstructured":"Winkler G, Wittmann I. Fat tissue as the primary target organ of\n insulin resistance in diabetes mellitus. [A zs\u00edrsz\u00f6vet mint a 2-es t\u00edpus\u00fa\n diabetest k\u00eds\u00e9r\u0151 inzulinrezisztencia egyik c\u00e9lszerve.] Orv Hetil. 2023; 164:\n 3\u201310. [Hungarian]","DOI":"10.1556\/650.2023.32680"},{"key":"R35","doi-asserted-by":"crossref","unstructured":"Targher G, Lonardo A, Byrne CD. Nonalcoholic fatty liver disease and\n chronic vascular complications of diabetes mellitus. Nat Rev Endocrinol. 2018;\n 14: 99\u2013114.","DOI":"10.1038\/nrendo.2017.173"},{"key":"R36","doi-asserted-by":"crossref","unstructured":"Alessi MC, Bastelica D, Mavri A, et al. Plasma PAI-1 levels are more\n strongly related to liver steatosis than to adipose tissue accumulation.\n Arterioscler Thromb Vasc Biol. 2003; 23: 1262\u20131268.","DOI":"10.1161\/01.ATV.0000077401.36885.BB"},{"key":"R37","doi-asserted-by":"crossref","unstructured":"Caussy C, Aubin A, Loomba R. The relationship between type 2\n diabetes, NAFLD, and cardiovascular risk. Curr Diab Rep. 2021; 21:\n 15.","DOI":"10.1007\/s11892-021-01383-7"},{"key":"R38","doi-asserted-by":"crossref","unstructured":"Lonardo A, Mantovani A, Targher G, et al. Nonalcoholic fatty liver\n disease and chronic kidney disease: epidemiology, pathogenesis, and clinical and\n research implications. Int J Mol Sci. 2022; 23: 13320.","DOI":"10.3390\/ijms232113320"},{"key":"R39","doi-asserted-by":"crossref","unstructured":"P\u00e1r G. Non-invasive tests for evaluation of the severity and\n prognosis of liver diseases. [A m\u00e1jbetegs\u00e9gek s\u00falyoss\u00e1g\u00e1nak \u00e9s progn\u00f3zis\u00e1nak nem\n invaz\u00edv vizsg\u00e1l\u00f3m\u00f3dszerei.] Orv Hetil. 2023; 164: 847\u2013858.\n [Hungarian]","DOI":"10.1556\/650.2023.32780"},{"key":"R40","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver. Berzigotti A,\n Tsochatzis E, Boursier J, et al. Clinical Practice Guidelines on non-invasive\n tests for evaluation of liver disease severity and prognosis \u2013 2021 update. J\n Hepatol. 2021; 75: 659\u2013689.","DOI":"10.1016\/j.jhep.2021.05.025"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/www.akjournals.com\/view\/journals\/650\/166\/20\/article-p759.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/650\/166\/20\/article-p759.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/650\/166\/20\/article-p759.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:54:49Z","timestamp":1785419689000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.akjournals.com\/view\/journals\/650\/166\/20\/article-p759.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,18]]},"references-count":40,"journal-issue":{"issue":"20"},"URL":"https:\/\/doi.org\/10.1556\/650.2025.33294","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,18]]}}}